Alzheimer's Disease/ Senile Dementia of the Alzheimer's Type
Principal Investigator
Khalid Iqbal, PhD
New York State Institute for Basic Research in Developmental Disabilities
Staten Island, NY, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$116,972
Active Dates
April 01, 1988 - March 31, 1990
Grant ID
A1988028
Summary
In the brain of patients with Alzheimer disease the nerve cells accumulate mass of aberrant filaments, the paired helical filaments (PHF). The number of these fibril accumulations. the neur ofibrillary tangles correlate strongly with the degree of dementia in the affected patients. Microtubule associated protein tau which stimulates microtubule assembly and maintain polymerized microtubules is one of the major components of PHF. Tau in PHF is abnormally phosphorylated. A novel tau peptide has been identified by amino acid sequencing. This peptide is also present in PHF. The access of tau peptide antibodies to PHF requires dephosphorylation of PHF confirming that tau in PHF is abnormally phosphorylated. The presence of abnormally phosphorylated tau is observed both in neurons with tangles and in some neurons where tangles are not detectable with silverstains. These studies suggest that tau in PHF is abnormally phosphorylated and that the accumulation of abnormally phosphorylated tau in the affected neurons precede the formation of the tangles. Studies on the site and nature of the abnormal phosphorylation of tau which will help elucidate the pathogenesis of Alzheimer disease are presently underway
Grants
Related Grants
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Alzheimer's Disease Research
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD